On the heels of its second quarter earnings call, analysts are looking at Biogen ( BIIB ) as both a potential buyer and takeover target in the biotech sector. Biogen, a biotech company based in Cambridge, Mass. highlighted its M&A strategy during its second quarter earnings call July 21, in addition to announcing that its CEO, George Scangos, is stepping down. "We would look at deals at all stages of development," George Scangos, the company's CEO who announced his resignation during the call said. "We are in a number of discussions now." The company also noted that it's primarily looking into targets within the neurology sector of biotech. But the fact that Scangos has decided to step down has led some to believe that the company will opt to sell itself or split up. Analyst Michael Yee of RBC Capital said during an interview that the company could be purchased by Roche ( RHHBY ), which already has a partnership with the company.